Advaxis Inc
F:FAD2
Advaxis Inc
Goodwill
Advaxis Inc
Goodwill Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Goodwill | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Advaxis Inc
F:FAD2
|
Goodwill
$4.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Goodwill
$35.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Goodwill
$8.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
22%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Goodwill
$18.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
5%
|
CAGR 10-Years
2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Goodwill
$1.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
41%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Advaxis Inc
Glance View
Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. The company is headquartered in Monmouth Junction, New Jersey and currently employs 15 full-time employees. The company went IPO on 2005-07-28. The Company’s products are based on a platform technology, which utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. The company is focused on single antigen and multiple antigen delivery products. The firm's pipeline of product candidates includes ADXS-503, which develops for treatment of non-small cell lung cancer; ADXS-504, which develops for the treatment of early-stage prostate cancer; and ADXS-PSA, which develops for the treatment of metastatic prostate cancer. Its ADXS-503 and ADXS-503 are in Phase I clinical trial. ADXS-PSA is in Phase II clinical trial. The company has completed and closed out clinical studies of Lm Technology immunotherapies in three program areas, HPV associated cancers, Personalized neoantigen-directed therapies and PSA directed therapy.
See Also
What is Advaxis Inc's Goodwill?
Goodwill
4.5m
USD
Based on the financial report for Dec 31, 2023, Advaxis Inc's Goodwill amounts to 4.5m USD.
